Please ensure Javascript is enabled for purposes of website accessibility

Moderna Advances Coronavirus Vaccine to the Next Phase

By Jim Crumly - Apr 28, 2020 at 3:22PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech applied for approval to move to phase 2 testing, which it expects to start this quarter.

Clinical-stage biotech Moderna (MRNA 0.70%) announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to move its COVID-19 vaccine to phase 2 and late-stage studies if supported by safety data from a phase 1 trial underway now.

Moderna has received feedback from the FDA on the design of the study and expects to begin the phase 2 trial of its vaccine candidate mRNA-1273 in the next two months. The trial will enroll 600 participants, who will be randomly assigned to groups receiving a placebo or one of two dose levels of the vaccine, given as two different vaccinations 28 days apart. Half of the participants will be between the ages of 18 and 55 and the other half 55 or older. Participants will be followed for a year after the last vaccinations.

Four coronavirus particles with a double helix in the background

Image source: Getty Images.

Moderna's candidate to fight the SARS-CoV-2 virus is currently in a phase 1 study in partnership with the National Institute of Allergy and Infectious Diseases (NIAID), and is based on the company's proprietary technology centered on messenger RNA, or mRNA. That study initially enrolled 45 healthy adults and is currently expanding to enroll three cohorts of older adults between 56 and 70 and three cohorts of adults aged 71 years and above.

The company was fast out of the gate in the race for a vaccine, completing the first batch on Feb. 7 and dosing the first test subject on March 16. If results from the first two phases of trials are positive, Moderna said that it could begin phase 3 studies in the fall of 2020.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$144.27 (0.70%) $1.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
336%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.